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OBJECTIVE— Incidence of type 2 diabetes might be associated with preexisting hyperten-
sion. There is no information on whether incident diabetes is predicted by blood pressure
control. We evaluated the hazard of diabetes in relation to blood pressure control in treated
hypertensive patients.
RESEARCH DESIGN AND METHODS— Nondiabetic, otherwise healthy, hyperten-
sive patients (N 1,754, mean SD age 52 11 years, 43% women) participated in a network
over 3.4  1 years of follow-up. Blood pressure was considered uncontrolled if systolic was
140 mmHg and/or diastolic was90 mmHg at the last outpatient visit. Diabetes was defined
according to American Diabetes Association guidelines.
RESULTS— Uncontrolled blood pressure despite antihypertensive treatment was found in
712 patients (41%). At baseline, patients with uncontrolled blood pressure were slightly younger
than patients with controlled blood pressure (51  11 vs. 53  12 years, P  0.001), with no
differences in sex distribution, BMI, duration of hypertension, baseline blood pressure, fasting
glucose, serum creatinine and potassium, lipid profile, or prevalence of metabolic syndrome.
During follow-up, 109 subjects developed diabetes. Incidence of diabetes was significantly
higher in patients with uncontrolled (8%) than in those with controlled blood pressure (4%,
odds ratio 2.08, P 0.0001). In Cox regression analysis controlling for baseline systolic blood
pressure and BMI, family history of diabetes, and physical activity, uncontrolled blood pressure
doubled the risk of incident diabetes (hazard ratio [HR] 2.10, P  0.001), independently of
significant effects of age (HR 1.02 per year, P 0.03) and baseline fasting glucose (HR 1.10 per
mg/dl, P  0.001).
CONCLUSIONS— In a large sample of treated nondiabetic hypertensive subjects, uncon-
trolled blood pressure is associated with twofold increased risk of incident diabetes indepen-
dently of age, BMI, baseline blood pressure, or fasting glucose.
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A rterial hypertension is common inpatients with type 2 diabetes. A sur-vey of over 1,500 patients with di-
abetes, conducted between 1988 and
1994, determined that 60 – 80% had
blood pressure higher than 130/85
mmHg or had been prescribed antihy-
pertensive medication (1). Results from
MRFIT (Multiple Risk Factor Intervention
Trial) indicated that diabetes confers
greater cardiovascular risk for compara-
ble levels of other cardiovascular risk fac-
tors, suggesting that blood pressure
control should be more rigorous in the
presence of diabetes (2). However, there
is no clearly defined temporal relation-
ship between diabetes and hypertension.
Incidence of type 2 diabetes, in fact,
also increases with increased baseline
blood pressure in women without preva-
lent diabetes, based on modified blood
pressure categories from the 2007 Euro-
pean Society of Hypertension/European
Society of Cardiology (ESH/ESC) guide-
lines (3). There is increasing evidence of a
substantial interplay of metabolic factors
with arterial hypertension (4,5). We have
recently shown that optimal control of
blood pressure is blunted by coexisting
metabolic risk factors, clustering the phe-
notype of metabolic syndrome (4). There
is no information about whether subopti-
mal control of blood pressure might also
be associated with incident diabetes, inde-
pendently of confounders. Accordingly, we
tested the hypothesis that insufficient con-
trol of blood pressure is an independent risk
factor for diabetes in a cohort of hyperten-
sive patients with initial normal fasting
plasma glucose.
RESEARCH DESIGN AND
METHODS— As previously reported
(6), beginning in 1997 we generated a
network, the Campania Salute Network,
among the Hypertension Center of the Fe-
derico II University Hospital (Naples, It-
aly), 23 community hospital– based
hypertension clinics, and 60 general prac-
titioners from our district area, including
over 12,000 cardiovascular patients, of
whom 10,254 had arterial hypertension.
Among hypertensive subjects, 7,422 were
initially free of prevalent cardiovascular
disease (6). Prevalent cardiovascular dis-
ease was defined at each patient’s first ex-
amination in our outpatient clinic, and
criteria included previous myocardial in-
farction, angina, or procedures of coro-
nary revascularization; stroke or transient
ischemic attack; or congestive heart fail-
ure. Prevalent cardiovascular disease was
excluded by the Committee for Event Ad-
judication in the Hypertension Center
and was based on patient history, contact
with the reference general practitioner,
and clinical records documenting occur-
rence of disease.
Criteria for selection in the present
study included the availability of fol-
low-up data for at least 2 years and ab-
sence of diabetes at the time of the first
visit. According to these criteria, we ex-
cluded 5,668 patients: 4,957 with 2
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years of follow-up (3,258 due to enroll-
ment in the past 2 years and 1,699 lost to
follow-up), 386 with prevalent diabetes,
and 325 with reported impaired fasting
glucose at the time of the first visit. Thus,
we analyzed 1,754 Caucasian hyperten-
sive patients (43% women mean  SD
age 52  11 years) with normal fasting
glucose who had been followed up for
3.5  1.8 years. All eligible participants
underwent at least two control visits after
the first examination.
The database generation of the Cam-
pania Salute Network was approved by
the Federico II University Hospital Ethic
Committee. Signed informed consent for
the possibility of using data for scientific
purposes was obtained.
Laboratory tests and definitions
Fasting plasma glucose and lipid profiles
were measured by standard methods.
Glomerular filtration rate (GFR) was esti-
mated from serum creatinine by the mod-
ified MDRD (Modification of Diet in Renal
Disease) equation (7).
According to a questionnaire, pa-
tients were asked to classify their lifestyle
as sedentary or nonsedentary. This infor-
mation was used in the analysis as a raw
indicator of physical activity.
Systolic and diastolic blood pressure
was measured at each visit by a standard
sphygmomanometer after patients had
been in a sitting position for 5 min, ac-
cording to ESH/ESC guidelines (8). For
each patient, three blood pressure mea-
surements were obtained at 2-min inter-
vals while the patient was in the sitting
position. The average of these measure-
ments was used for the analysis (8).
BMI was calculated at each visit; pa-
tients with values30 kg/m2 were classi-
fied as obese and were assumed to have
central fat distribution (9). Diagnosis of
metabolic syndrome was, therefore, is-
sued according to modified Adult Treat-
ment Panel (ATP)-III criteria (4,5) and
required at least two of the following met-
abolic risk factors: plasma triglycerides
150 mg/dl, fasting plasma glucose
110 mg/dl, HDL cholesterol40 mg/dl
for men or 50 mg/dl for women, and
BMI 30 kg/m2 (as a surrogate of in-
creased waist girth). Non-HDL choles-
terol was also determined and was
calculated as the difference between total
and HDL cholesterol.
The number of antihypertensive
medications used at the time of each visit
was also evaluated. Blood pressure was
considered controlled at140/90 mmHg
and otherwise considered uncontrolled.
Reported medical diagnostic codes for di-
abetes and prescriptions of oral hypogly-
cemic drugs or insulin were used to
identify prevalent and incident cases of
diabetes. Prevalent and incident diabetes
was diagnosed when fasting plasma
glucose was 125 mg/dl, according to
American Diabetes Association guide-
lines (10).
Statistical analysis
Data were analyzed using SPSS (version
12.0; SPSS, Chicago, IL) and expressed as
means  1 SD. All variables deviating
from normal distribution were log trans-
formed before parametric statistics were
calculated. Descriptive statistics were per-
formed using ANOVA or 2 distribution,
with Monte Carlo simulation to generate
exact P values.
The last available blood pressure
value was used to classify controlled and
uncontrolled patients. For patients devel-
oping diabetes, we used the last available
controlled blood pressure value before
diabetes was diagnosed. Incidence of
diabetes in relation to controlled or un-
controlled blood pressure was evaluated
using Cox regression, by the enter proce-
dure, controlling for baseline values of
age, sex, BMI, fasting plasma glucose,
family history of diabetes, blood pressure
at the time of the first visit, and sedentary
or nonsedentary lifestyle. Alternative
models were also computed using the last
available blood pressure value instead of
categories of controlled/uncontrolled
blood pressure.
To account for therapy in the Cox
model, single classes of medications, in-
cluding anti–renin-angiotensin system
(RAS) drugs (ACE inhibitors and/or AT1
receptor antagonists), calcium-channel
blockers (CCBs),-blockers, and thiazide
diuretics, were dichotomized according
to their overall use during the individual
follow-up, based on the frequency of pre-
scription during the control visits. Thus,
all medications used for more than 50% of
control visits were considered as covari-
ates in a new proportional hazards analysis.
In this Cox model, we used a hierarchical
model with a 1st step in which all covariates
used in the previous Cox analysis were en-
tered by a backward model-building proce-
dure (P to enter 0.05 and P to remove
0.15) and a 2nd step in which the classes
of medications were thereafter forced into
the model.
RESULTS— Uncontrolled blood pres-
sure despite therapy was found in 712 pa-
tients (41% of population). Baseline
characteristics in relation to control of
blood pressure are shown in Table 1. At
baseline, patients with subsequent un-
controlled blood pressure were younger
(P  0.001) and had a higher heart rate
(P  0.02) than patients with controlled
blood pressure, with no differences in sex
distribution, BMI, reported duration of
hypertension, baseline blood pressure
values, metabolic profile (glucose, uric
acid, and lipids), serum creatinine and
electrolytes, GFR, or prevalence of meta-
bolic syndrome. Uncontrolled blood
pressure was also associated with a
slightly reduced number of control visits
over the follow-up period (P  0.05).
During follow-up, 109 patients (6%
of the population, 41% women) devel-
oped diabetes. At baseline, patients with
subsequent diabetes were older (56.2 
9.7 vs. 51.6 11.6 years) and had greater
BMI (29.2 4 vs. 27.3 4 kg/m2), fast-
ing glucose (107.9  10 vs. 92.5  11.6
mg/dl), uric acid (5.7 1.8 vs. 5.0 1.5
mg/dl), plasma triglycerides (169.4 
112.7 vs. 126.5 68.4 mg/dl), and prev-
alence of metabolic syndrome (60.7 vs.
21.4%) than patients without incident di-
abetes (all P 0.001). In univariate cross-
tabulation, incident diabetes was 35%
less in nonsedentary than in sedentary
participants (odds ratio [OR] 0.65 [95%
CI 0.44–0.97], P 0.041). Reported du-
ration of hypertension was also longer
(8.7  7.5 vs. 6.8  6.7 years, P 
0.013), and family history of diabetes was
more frequent (8.2 vs. 5.1%, P 0.017).
In univariate cross-tabulation, incident
diabetes was 2.45-fold higher in partici-
pants with BMI 30 kg/m2 (2.45 [1.62–
3.71], P  0.0001). No differences were
found in sex distribution, number of visits
per year, baseline blood pressure and
heart rate, serum creatinine and electro-
lytes, GFR, total cholesterol, HDL choles-
terol, and uric acid. There was no
significant variation of BMI over time in
either group.
Prediction of incident diabetes and
blood pressure control
Risk of incident diabetes was significantly
higher in patients with uncontrolled (8%)
than in those with controlled blood pres-
sure (4%, OR 2.08, P  0.0001). In Cox
analysis controlling for age at the time of
the first visit, sex, baseline values of sys-
tolic blood pressure, family history of di-
abetes, fasting glucose, BMI, and reported
Diabetes and blood pressure control
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physical activity, incident diabetes re-
mained more than twofold higher in pa-
tients with uncontrolled than in those
with controlled blood pressure (hazard
ratio [HR] 2.1 [95% CI 1.41–3.12], P 
0.0003), with additional significant ef-
fects for higher baseline fasting glucose
(1.1 [1.08–1.13], P 0.0001) and older
age (1.02 [1.00–1.04], P 0.03) and no
detectable effect for the other covariates
(Fig. 1). Wald statistics suggest that fast-
ing plasma glucose was the strongest
predictor of incident diabetes and that
suboptimal control of blood pressure
was the second strongest predictor.
Alternative Cox models were gener-
ated using blood pressure as a continuous
variable rather than dichotomizing it into
controlled and uncontrolled. In these al-
ternative models, both systolic (not dia-
stolic) blood pressure (HR 1.02 per
mmHg [95% CI 1.01–1.03], P  0.01)
and mean blood pressure (1.03 per
mmHg [1.01–1.06], P  0.01) were sig-
nificant, independent predictors of inci-
dent diabetes.
In another Cox model, using the
modified ATP-III definition of metabolic
syndrome instead of fasting plasma
glucose and BMI, together with the risk
of incident diabetes associated with
metabolic syndrome (HR 4.4 [95% CI
2.9 – 6.7]), uncontrolled blood pressure
maintained or even increased its predic-
tive value (2.7 [1.7– 4.1], both P 
0.0001).
Antihypertensive therapy
During follow-up, slightly more antihy-
pertensive medications were prescribed
in patients with controlled than in those
with uncontrolled blood pressure
(1.57 0.94 vs. 1.47 0.90 drugs, P
0.03). Single classes of antihypertensive
medications were, therefore, examined in
relation to incident diabetes, and the fre-
quency of use over the entire follow-up
time in censored and uncensored obser-
vations was considered. We arbitrarily
evaluated medications prescribed in more
than 50% of available visits. Because of
potential pharmacological interaction fa-
voring development of diabetes, the asso-
ciation between thiazides and -blockers
was also specifically examined. Thus, the
classes of antihypertensive medications
analyzed were thiazides, -blockers, anti-
RAS drugs, CCBs, and combinations of
thiazides and -blockers.
The frequency of prescription of
-blockers was twofold higher in patients
with incident diabetes than in those with-
out incident diabetes (HR 2.04 [95% CI
1.36–3.07], P 0.0008). Similarly, com-
binations of thiazides and -blockers
were threefold more frequent in patients
with than in those without incident dia-
betes (3.00 [1.72–5.26], P  0.0002).
There was no difference in prescriptions
for thiazides without -blockers, anti-
RAS drugs, or CCBs. Another Cox model
was, therefore, generated including
classes of antihypertensive medications in
addition to the covariates used in the pre-
vious Cox model. Table 2 shows that un-
controlled blood pressure retained a
nearly twofold higher probability of asso-
ciation with incident diabetes, indepen-
dently of all covariates, including
treatment. In this model, additional sig-
nificant predictors were older age, higher
baseline fasting glucose, higher BMI, and
therapy with -blockers (Table 2).
CONCLUSIONS— In this study, for
the first time we demonstrate that subop-
timal control of blood pressure is a strong
predictor of incident type 2 diabetes in
initially normoglycemic, hypertensive in-
Figure 1—Cumulative hazard of incident diabetes in nondiabetic hypertensive patients under antihypertensive therapy in relation to blood pressure
control, after adjusting for age, sex, systolic blood pressure, family history of diabetes, BMI, and plasma glucose at baseline (see text for explanation).
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dividuals after a follow-up of at least 2
years on antihypertensive treatment. This
effect is independent of age, baseline fast-
ing glucose, presence of metabolic syn-
drome, and type of antihypertensive
therapy. Prescription of -blockers, but
not of thiazides, is also strongly and inde-
pendently associated with new onset of
diabetes.
Our findings extend previous obser-
vations indicating that incident type 2 di-
abetes is more frequent in hypertensive
than in normotensive subjects (3,11). In
particular, Conen et al. (3) recently re-
ported a clear correlation between higher
incidence of type 2 diabetes and blood
pressure levels in a large population of
women, based on modified categories
from the 2007 ESH/ESC guidelines.
The relation between suboptimal
control of blood pressure and incident di-
abetes also paralleled evidence of differ-
ent follow-up profiles in censored and
uncensored individuals. Patients with in-
cident diabetes underwent fewer visits
each year, were prescribed fewer medica-
tions, and presented with a larger BMI. It
is possible that a less attentive adherence
to the suggestions of the specialist both in
terms of compliance to the treatment and
changes in lifestyle could be at least in
part associated with the increased risk of
developing diabetes. However, this possi-
bility was partly contradicted by our pre-
vious demonstration that the phenotype
of metabolic syndrome, a potent risk factor
for diabetes in our analysis also, is associ-
ated with a high likelihood of uncontrolled
blood pressure, despite the greater number
of prescribed medications.
The other interesting aspect emerging
from our analysis is the evidence of the
independent relation of -blocker ther-
apy to the incidence of diabetes, which
was consistent with recent literature (12).
In contrast, diuretic therapy did not inde-
pendently predict diabetes, a finding that
was inconsistent with some (13) but not
all studies (11,14). Gress et al. (11) have
shown no significant, independent effect
of thiazides in their population-based
study once demographic, environmental,
and metabolic cofactors were taken into
account. In the ALLHAT (Antihyperten-
sive and Lipid-Lowering Treatment to
Prevent Heart Attack Trial) study, other
than adjustment for chlorthalidone and
increased risk of diabetes after 2 and 4
years (14), no multivariate adjustment
comparable with that used in the model of
the present study was attempted to verify
whether this effect was independent of
confounders. In addition, whereas in the
ALLHAT study design diuretic therapy
was not associated with any anti-RAS
medication (and in fact K levels were
significantly lower in the group on diuret-
ics), in all analyzed patients in the present
study thiazides were associated with other
medications and K levels were indistin-
guishable between the groups. Another
characteristic to consider in our popula-
tion is that thiazides were used at very low
doses. There is some evidence that thia-
zides may also produce or increase he-
patic insulin resistance, but this effect is
dose dependent and associated with hy-
pokalemia (15).
The two main findings in our study
(i.e., regarding the relation of uncon-
trolled blood pressure and use of-block-
ers to incident diabetes) are biologically
plausible and in accord with most recent
findings suggesting that microvascular al-
terations might precede development of
diabetes (16). Because the goal of our
study was to assess the risk of incident
diabetes in poorly controlled hyperten-
sive patients, independent of therapeutic
aggressiveness (and therefore including
patients with possible suboptimal therapy
at the time of censoring), these findings
suggest that the timing of achieving target
blood pressure values might also be sub-
stantially relevant to preventing diabetes,
Table 1—Demographic, clinical, and laboratory characteristics of the study population
Controlled blood
pressure
Uncontrolled blood
pressure P 
n 1,042 712
Age (years) 52.7  11.6 50.6  11.3 0.0001
Sex (%M/F) 58/42 56/44 NS
BMI (kg/m2) 27.3  3.9 27.6  4.1 NS
Reported duration of hypertension (years) 7.2  7.1 6.5  6.3 NS
Visits per year (n) 2.34  1.03 2.25  1.02 0.047
Systolic blood pressure (mmHg) 159.8  21.8 158.0  19.2 NS
Diastolic blood pressure (mmHg) 99.6  10.8 99.6  10.2 NS
Heart rate (bpm) 71.87  11.29 73.16  12.58 0.028
Fasting glucose (mg/dl) 93.5  12.2 93.2  12.0 NS
Uric acid (mg/dl) 5.1  1.4 5.1  1.7 NS
Blood urea nitrogen (mg/dl) 37.6  10.1 36.3  11.8 NS
Serum creatinine (mg/dl) 0.94  0.2 0.93  0.2 NS
GFR (ml/min) 82.7  19.9 83.7  19.1 NS
K (mEq/l) 4.4  0.4 4.4  0.4 NS
Na (mEq/l) 141.2  3.3 141.3  3.1 NS
Cholesterol (mg/dl) 206.5  38.6 207.2  37.4 NS
HDL cholesterol (mg/dl) 50.2  12.3 50.7  12.7 NS
Non-HDL cholesterolemia (mg/dl) 156.5  37.9 156.7  37.7 NS
Triglycerides (mg/dl) 129.2  67.7 128.8  79.0 NS
Metabolic syndrome (%) 24.2 23.6 NS
Data are means  SD or percentage of the relevant group of patients. NS, not significant.
Table 2—Hazard of incident diabetes in nondiabetic, treated hypertensive patients, including
classes of antihypertensive medications
B Wald P  HR
95.0% CI
Lower Upper
Fasting glucose (mg/dl) 1.07 1.12
BMI (kg/m2) 0.03 7.09 0.01 1.08 1.02 1.14
Age (years) 0.03 6.33 0.014 1.03 1.01 1.05
Sex (M/F) 0.03 0.02 0.9 1.03 0.67 1.60
Thiazide diuretics 0.28 1.73 0.21 0.75 0.48 1.18
-Blockers 0.77 13.05 0.0001 2.17 1.41 3.34
Anti-RAS drugs 0.12 0.19 0.65 1.12 0.68 1.86
Suboptimal blood pressure control 0.63 7.58 0.004 1.88 1.23 2.88
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a possibility that should be tested in ad
hoc clinical trials.
The temporal sequence observed in
our study suggests some possibilities to be
explored in future research. First, both
hypertension and diabetes might share a
common abnormality of microvascular
function that might be corrected by anti-
hypertensive therapy. When generalized,
dysfunction is more easily detectable with
increased blood pressure than with meta-
bolic alterations preceding diabetes,
which provides an explanation for hyper-
tension appearing before diabetes. This
hypothesis is supported by increasing ev-
idence that microvascular dysfunction
might be the background abnormality in
experimental diabetes (17). However, al-
though vascular rarefaction has been gen-
erally suggested to contribute to insulin
resistance (17), a cause-and-effect rela-
tionship has not been demonstrated.
Another possibility is that the lack of
effective control of blood pressure paral-
lels persistent neurohormonal abnormal-
ities, including potential defects in the
sympathetic system (18) and/or RAS ac-
tivity (19), which in the long run partici-
pate in the precipitation of diabetes.
The unfavorable metabolic conse-
quence of -blockade is likely due to de-
creased insulin sensitivity, which is also
demonstrated in hypertensive patients
(20), associated with insulin-related met-
abolic features (21) and deleterious ef-
fects on insulin secretion (22). As widely
reported, insulin resistance evolves into
diabetes once-cell failure occurs (23). In
addition to this mechanism, -receptor
blockade might favor enhancement of he-
patic glucose output, which has been
demonstrated in rats but not humans (24).
A potential limitation of this study is
the absence of direct information on body
fat distribution. Because of this limitation,
in addition to our use of BMI as a contin-
uous variable, we used a cut point of BMI
to categorize obesity. The cut point of BMI
for obesity has been previously used as a
surrogate of waist girth in studies on met-
abolic syndrome, and the International
Diabetes Federation indicates that when
BMI is in the range of obesity, a central fat
distribution can be assumed. In addition,
at least in terms of prediction of diabetes,
BMI has been shown to be as informative
as waist circumference, waist-to-hip ratio,
or direct visceral fat measured by com-
puted tomography (25). Finally, the prev-
alence of obesity in this population is
likely affected by our initial selection,
which excluded subjects with type 2 dia-
betes or impaired fasting glucose at base-
line examination.
Another potential limitation of this
study is the unavailability of information
regarding albuminuria because the data
collection was initiated at a time when al-
buminuria was not yet required as a pri-
mary workup test in all outpatients.
According to selection criteria in the
present study, we included relatively
healthy patients who did not require as-
sessment of albuminuria.
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